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Background: To report the effect of subtenon injections of natural leukocyte interferon α-2a (IFNα) on best
corrected visual acuity (BCVA) and central macular thickness (CMT) in a patient with diabetic macular edema (DME).
Case presentation: A 66-year-old man affected by DME, with glycated hemoglobin (HbA1c) at 6.9%, refractory to
laser grid treatment and intravitreal injections of triamcinolone, was selected to receive a cycle of three subtenon
injections/week of IFNα (1×106 IU/ml). BCVA and CMT, using spectral domain ocular coherence tomography
(SD-OCT), were evaluated preoperatively and at 1 week, 1 month, 4 months, and 1 year postoperatively. BCVA and
CMT were significantly improved at 1 week after the three injections (20/200 vs. 20/40 and 498 μm vs. 237 μm,
respectively). BCVA remained stable during the 1-year follow-up. CMT was slightly increased, but was still lower than
the baseline value (215 μm, 255 μm, and 299 μm during the follow-up visits). No adverse events were recorded,
with the exception of mild subconjunctival hemorrhage at the injection site.
Conclusions: IFNα, with its immunomodulatory, anti-proliferative and anti-angiogenic actions, was effective in
improving BCVA and reducing CMT in refractory DME. Further randomized controlled studies are required to assess
the effect of IFNα alone or in combination with other therapies for DME treatment.
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Diabetes mellitus (DM) is a common disease and the
macular edema it causes is the leading cause of visual
loss around the world. Diabetic macular edema (DME)
is due to the breakdown of the blood-retinal barrier
secondary to complex biochemical dysregulation [1].
Despite focal and/or grid argon laser photocoagulation,
which is considered the standard of care in clinically
significant DME, a distinct subgroup of eyes with
DME is resistant to conventional laser therapy, with
visual acuity continuing to decline [2].
More recently, the role of oxidative stress, inflammatory
mediators (like interleukin [IL]-6, IL-8, monocyte chemo-
tactic protein-1, tumor necrosis factor [TNF-α], protein
kinase [CPKC-β], nitric oxide synthase, nuclear factor
kappa-light-chain-enhancer of activated B cells [NF-κB])
and the up-regulation of vascular endothelial growth factor* Correspondence: mauro.cellini@unibo.it
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reproduction in any medium, provided the or(VEGF) in DME have been elucidated [1]. Thus, intravitreal
(IV) injections of corticosteroids [3] and/or anti-VEGF
drugs [4] have been proposed alone or in combination to
treat DME.
However, these treatments have drawbacks. For example,
IV injection of corticosteroids shows short-term effects
and high rates of intraocular complications [3], whereas
anti-angiogenic drugs provide a definite, but small, benefit
compared to current therapeutic options for DME
(i.e., grid laser photocoagulation), requiring also a large
number of injections and high costs [4].
Interferons belong to a large class of glycoproteins
known as cytokines and are released by host cells in
response to the presence of pathogens or tumor cells.
Interferons have anti-viral, immunomodulatory, and
anti-proliferative properties, inhibiting VEGF and other
cytokines like IL-8, IL-10, tumor growth factor [TGF-β],
and TNF-α [5], while enhancing the barrier function of
the retinal microvascular endothelium in vitro [6].
In some cases, we have used these anti-proliferative
and anti-VEGF properties, with an off-label subtenontd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Central macular thickness (CMT) modification during
the follow-up visits measured with spectral domain optical
coherence tomography. At baseline, CMT was 497 μm (a); one
week after 3 posterior subtenon injections of natural leucocytic
interferon-α 2a. CMT decreased to 237 μm (b); after 1 month (c),
3 months (d) and 1 year (e) CMT was 215, 255 and
299 μm, respectively.
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edema [7] and age-related choroidal neovascularization
[8] and we have followed them for a period of 4 months
reporting good results.
This case report highlights, for the first time, the effect
of subtenon injections of natural leukocyte interferon
α-2a (IFNα) on best corrected visual acuity (BCVA)
and central macular thickness (CMT) in a patient affected
by refractory DME after one year that the treatment was
stopped.
Case presentation
A 66-year-old man, affected by type II DM for 4 years
and arterial hypertension for 10 years, developed severe
non-proliferative diabetic retinopathy without macular
edema just 2 years after DM diagnosis. The patient was
treated with panretinal photocoagulation (PRP), because
he had a poor glycometabolic control and was unable to
adhere to a close follow-up. One year after PRP, he
developed severe visual loss due to diffuse non tractional
bilateral DME. Thus, the two eyes were treated with an
IV triamcinolone injection 1 month apart (the right eye
[RE] before the left eye [LE]) and laser grid photocoagula-
tion was performed in both eyes 2 weeks after IV injection.
After no visual recovery for over 2 months due to the per-
sistence of macular edema in both eyes, an IV injection of
bevacizumab was given in the RE, where a larger amount
of intraretinal fluid and subfoveal neural detachment were
observed. However, 1 week after the injection, anterior
ischemic optic neuropathy (AION) with a residual visual
acuity of hand motion was observed. During the entire
period, the patient had poor glycometabolic control
(glycated hemoglobin >9%, high hypertension, and
hypercholesterolemia) and poor adherence to therapy.
This fact could have influenced the patient’s poor response
to therapy and the development of AION.
As a result of this unfortunate adverse event, the patient
refused an IV injection of bevacizumab in his LE. After
informing the patient about the risks and benefits of
different treatment options such as observation, off-label
IV injections of steroids, and subtenon injections of IFNα,
the patient signed an informed consent for a cycle of
subtenon injections of IFNα.
Before the treatment, the BCVA in the LE was 20/200.
The patient received posterior subtenon injections of
IFNα (1×106 IU/ml) three times (on Monday, Wednesday,
and Friday) for a week in his LE, according to the following
procedure: after the administration of topical 0.4%
oxybuprocaine surface anesthesia, 1 ml of IFNα was
slowly injected into the inferotemporal quadrant
under the Tenon’s capsule, using a 27-gauge needle
on a 2.5-ml syringe. The needle was moved toward the
macular area, until the hub was firmly pressed against the
conjunctival fornix. After the first injection, topical 0.3%
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7 days. During the period of IFN-α therapy, the patient
had a good systemic condition and a good glycometabolic
control (glycated hemoglobin = 6.9%).
A complete ophthalmic examination including BCVA,
indirect ophthalmoscopy, and SD-OCT of the macular
region was conducted several times throughout the
period of IV injection and laser grid therapy and, specific-
ally, preoperatively, as well as at 1 week, 1 month, 4 months,
and 1 year after the last injection of INFα. SD-OCT images
were obtained using Spectralis OCT spectral-domain
(Heidelberg Engineering GmbH, Heidelberg, Germany)
and the baseline macular scan was set as the reference
(Figure 1). Fifteen months after the treatment, the BCVA
in the LE was 20/40, with reduced cystoid macular edema
but the SD-OCT highlighted the persistence of the photo-
receptor inner segment/outer segment (IS/OS) disruption
already highlighted at the baseline (Figure 2). The patient
gives his written consent for the use of his data and any
accompanying images.
Conclusion
This case report demonstrates that IFNα may be an
effective therapeutic option for refractory DME in patients
who show contraindications or complications from IV
anti-VEGF injections. Indeed, it may improve BCVA and
CMT by acting against different biochemical targets
involved in the pathogenesis of DME, such as VEGF, IL-8,Figure 2 Photoreceptor inner segment / outer segment (IS / OS) at th
focal presence (arrow) and the focal central disruption (arrow head) of the
treatment we found a decrease of focal central disruption (arrow head) ofIL-10, TGF-β, and TNF-α [5,6], even if its effect decreases
slightly over time. The disruption of the IS/OS may be
related not only to the period of about 1 year between the
onset of macular edema and the resorption of intraretinal
fluid [9] after IFN therapy, but also to an apoptotic action
of the IFN, with the formation of capsase-4 and −8 as
already noted with other anti-VEGF agents [10].
Due to its anti-inflammatory and anti-proliferative prop-
erties, intralesional injection of IFN has been used to treat
conjunctival lymphoma [11,12], while systemic IFN has
been applied to treat non-infectious uveitic chronic macu-
lar edema [13]. Within 2 to 4 weeks, approximately 94% of
patients were seen to reach a complete or partial remission
in the case of Behҫet disease-associated uveitis. Moreover,
IFNα is the only drug that leads to stable remission even
after the discontinuation of treatment [13]. A pilot study
provided evidence that systemic IFN may have a key role
in the regression of proliferative diabetic retinopathy [14].
Although IFNα is a large protein molecule, we decided
to administer it by subtenon injection because it can pene-
trate the sclera and enter the choroid, as demonstrated by
Lincoff [15]. In fact, after retrobulbar injection, IFNα
reaches higher intravitreal concentrations than systemic
injection and is well tolerated because a lower dosage is
required [15]. None of the adverse events described in the
literature after systemic IFN administration, such as
flu-like symptoms, leucopenia, or depression [13], were
found in our patient.e baseline and after 15 months of follow-up. The figure shows the
IS/OS layer before the IFN-α injections (a). Fifteen months after
the IS/OS layer (b).
Cellini et al. BMC Ophthalmology 2013, 13:63 Page 4 of 4
http://www.biomedcentral.com/1471-2415/13/63This case report provides evidence that IFNα might
have a role in the treatment of DME. However, further
randomized controlled studies are required to assess
the effect of IFNα alone or in combination with other
therapies for DME treatment.
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